Our CEO Joanna Shields chats with Julia Chatterly live on CNN, exploring the applications of AI in healthcare and how AI can be used to help find new medicines.
Read More
It’s been 50 years since the last treatment for Parkinson’s disease has been developed - patients are waiting too long for better treatments. We believe the application of AI holds huge potential to accelerate work towards a research breakthrough in Parkinson’s.
Read More
The potential of AI is difficult to ignore. From wearable devices carrying patient data allowing us to be guardians of our own medical history, to predictive analytics which will personalise our future medicinal therapies - AI is a powerhouse with the capacity to transform healthcare, and improve the lives of millions of people.
Read More
Joanna Shields gives the opening speech at CogX 2018 event about "Why AI matters to us all". “For more than a quarter century, we have been traveling at warp-speed and just as we emerge from the digital revolution we enter a new one -- and this one represents a quantum leap in terms of impact…”
Read More
A fun filled day organised at BenevolentAI this summer thinking on our values, reflecting on how to make great innovations and getting to know our international teams from NYC, London, Cambridge and Antwerp.
Read More
AI has the potential to positively and dramatically change our world. In healthcare, AI advances are being made in diagnosis and better care but is the technology capable of curing disease?
Read More
"If you come into my world, in biomedicine, everyday thousands of papers are uploaded in portal like PubMed, new genome sequences, new biomarkers, new clinical trial data, we are drowning in data [...] Artificial intelligence could be the solution for a broken drug discovery model."
Read More
Jackie Hunter, CEO BenevolentBio shares her thoughts on how Artificial Intelligence is accelerating drug discovery
Read More
Ken Mulvany, Founder, BenevolentAI, is interviewed by Hot Topics on BenevolentAI as a company and the challenge we are trying to solve. The interview includes how we are helping researchers to access and make sense of the enormous amount of data now available to them.
Read More
Professor Jackie Hunter is interviewed live on CNBC for their special AI series. Jackie talks about how BenevolentAI is applying AI technology to the drug discovery and development process, helping to access the vast amounts of data we see in the medical sciences every day:
Read More
Jackie Hunter, CEO BenevolentBio gave an interview to Innovation Forum and participated to a panel on how start-up-industry collaborations can be successfully initiated and maintained to drive innovation.
Read More
Matt Gooderick looks at the potential for the use of artificial intelligence in the health sector, including initiatives by IBM Watson, BenevolentAI and Babylon.
Read More
Listen to our founder Ken Mulvany discussing BenevolentAI's work on artificial intelligence applied to drug discovery.
Read More
Jackie Hunter talking about how Artificial Intelligence will be transformational in drug discovery and development at TechCrunch Disrupt London 2016.
Read More
Ken Mulvany, Co-founder and Director of BenevolentAI, discusses AI and machine learning with Information Age.
Read More
Watch this clip of the very first ‘supercomputer in a box’ – the NVIDIA DGX-1 – being delivered and unboxed by our resident experts Derek Wise and Dean Plumbley at BenevolentAI HQ. Being the first delivery of its kind in Europe, Derek and Dean explain how the processing power of the DGX-1 will hugely accelerate the work they and their colleagues are doing at the company.
Read More